242 Wythe Ave #4, Brooklyn, NY 11249

First Investment Date

Indaco Bio: October 2023


Indaco Bio


HQ – Basel, Switzerland – Rome, Italy


Biotech and Pharma



Investment Status


Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. The company is built on the knowledge of the Italian founding team with experience and success in the field of vaccine and immunotherapy for cancer. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens, or other immunomodulators, that has demonstrated to be clinically safe and to potently harness the power of the immune system.

Indaco participated in the Series C round that was co-led by Andera Partners, Bpifrance and M Ventures, with participation from Revelation Partners, Panakès Partners, XGen Ventures, together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Indaco has a Board Observer. The proceeds of the round will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline to achieve multiple clinical value catalysts.

Indaco Bio Fund invested into Nouscom in October 2023.